---
document_datetime: 2025-12-29 09:01:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/natalizumab-elan-pharma.html
document_name: natalizumab-elan-pharma.html
version: success
processing_time: 0.0619026
conversion_datetime: 2025-12-29 23:02:36.965353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Natalizumab Elan Pharma

[RSS](/en/individual-human-medicine.xml/65987)

##### Refused

This medicine has been refused authorisation

natalizumab Medicine Human Refused

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 July 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Natalizumab Elan Pharma concentrate for solution for infusion, intended for the treatment of Crohn's disease. The company that applied for authorisation is Elan Pharma International Ltd. The applicant requested a re-examination of the opinion. After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed their recommendation for the refusal of the marketing authorisation on 15 November 2007.

Questions and answers on the recommendation for the refusal of the marketing authorization for Natalizumab Elan Pharma

English (EN) (78.52 KB - PDF)

**First published:** 25/01/2008

**Last updated:** 25/01/2008

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_en.pdf)

[Other languages (21)](#file-language-dropdown-916)

български (BG) (184.21 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_bg.pdf)

español (ES) (77.16 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_es.pdf)

čeština (CS) (139.89 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_cs.pdf)

dansk (DA) (77.39 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_da.pdf)

Deutsch (DE) (80.69 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_de.pdf)

eesti keel (ET) (92.01 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_et.pdf)

ελληνικά (EL) (201.31 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_el.pdf)

français (FR) (77.23 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_fr.pdf)

italiano (IT) (92.4 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_it.pdf)

latviešu valoda (LV) (121.48 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_lv.pdf)

lietuvių kalba (LT) (118.8 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_lt.pdf)

magyar (HU) (117.8 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_hu.pdf)

Malti (MT) (156.18 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_mt.pdf)

Nederlands (NL) (77.96 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_nl.pdf)

polski (PL) (124.89 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_pl.pdf)

português (PT) (77.56 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_pt.pdf)

română (RO) (117.11 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_ro.pdf)

slovenčina (SK) (118.41 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_sk.pdf)

slovenščina (SL) (113.11 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_sl.pdf)

Suomi (FI) (75.75 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_fi.pdf)

svenska (SV) (95.1 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

25/01/2008

[View](/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_sv.pdf)

## Product details

Name of medicine Natalizumab Elan Pharma Active substance natalizumab International non-proprietary name (INN) or common name natalizumab Therapeutic area (MeSH) Crohn Disease Anatomical therapeutic chemical (ATC) code L03AD

### Pharmacotherapeutic group

Immunostimulants

## Application details

EMA product number EMEA/H/C/000624 Marketing authorisation applicant Elan Pharma International Ltd. Opinion adopted 15/11/2007 Refusal of marketing authorisation 11/01/2008

## Assessment history

Natalizumab Elan Pharma : EPAR - Refusal public assessment report

English (EN) (407.2 KB - PDF)

**First published:** 25/01/2008

**Last updated:** 25/01/2008

[View](/en/documents/assessment-report/natalizumab-elan-pharma-epar-refusal-public-assessment-report_en.pdf)

**This page was last updated on** 25/01/2008

## Share this page

[Back to top](#main-content)